ACTR3BP2: A Potential Drug Target and Biomarker (G440888)

Target Name: ACTR3BP2

NCBI ID: G440888

ACTR3BP2

Other Name(s): FKSG73 | ACTR3B pseudogene 2

ACTR3BP2: A Potential Drug Target and Biomarker

ACTR3BP2, also known as FKSG73, is a gene that encodes a protein involved in the detoxification of xenobiotics, such as polychlorinated biphenyls (PCBs) and polycyclic aromatic hydrocarbons (PAHs). Xenobiotics are widely used in agriculture and other industries as solvents, pigments, and in the production of other chemicals. However, these compounds have been linked to serious health problems, including reproductive and developmental problems, cancer, and neurotoxicity. The goal of this article is to discuss the potential implications of ACTR3BP2 as a drug target and biomarker.

The Dose-Effect Relationship of PCBs and Cancer

PCBs are known to be potent toxins that can cause serious health problems, including cancer. The most common form of PCB exposure is through the accidental ingestion of contaminated food or water. Studies have shown that exposure to low levels of PCBs can cause no harm, but exposure to higher levels can lead to serious health problems, such as reproductive and developmental problems, cancer, and neurotoxicity.

ACTR3BP2: A Potential Drug Target

The detoxification of PCBs by the liver is a critical process that helps to protect the body from the harmful effects of these compounds. The liver enzyme ACTR3BP2 is involved in this process. Activated forms of ACTR3BP2 include the active site mutants, which are altered in their activity and may disrupt the normal function of the enzyme.

Activation of PCBs by ACTR3BP2

Activation of PCBs by ACTR3BP2 is a complex process that involves multiple steps. The first step is the formation of an active metabolite, which is then transported to the liver. The second step is the detoxification of the metabolite by the liver enzyme ACTR3BP2. Activated forms of ACTR3BP2 have been shown to reduce the detoxification rate of PCBs, leading to increased levels of the metabolite in the body.

Activation of PCBs by ACTR3BP2 can also lead to the formation of toxic metabolites, such as 2-picoliningaldehyde (2-PA), which has been shown to be neurotoxic and can cause serious health problems, including cancer and neurodegenerative diseases.

The Role of ACTR3BP2 in Cancer

Activation of PCBs by ACTR3BP2 has been linked to the development of cancer. Studies have shown that individuals who have a genetic mutation that affects the activity of ACTR3BP2 are at a higher risk of developing cancer. Additionally, research has shown that activation of PCBs by ACTR3BP2 can lead to the formation of toxic metabolites, such as 2-PA, which has been shown to be neurotoxic and can cause cancer.

The potential drug target that ACTR3BP2 may serve as a biomarker is the inhibition of its activity, as this could lead to reduced levels of PCBs and the formation of toxic metabolites. This approach could be used to prevent the development of cancer and alleviate the symptoms associated with PCB exposure.

Conclusion

ACTR3BP2 is a gene that encodes a protein involved in the detoxification of xenobiotics, including PCBs. Activation of PCBs by ACTR3BP2 has been linked to the development of cancer and the formation of toxic metabolites. The potential drug target that ACTR3BP2 may serve as a biomarker is the inhibition of its activity, as this could lead to reduced levels of PCBs and the formation of toxic metabolites. Further research is needed to determine the full implications of ACTR3BP2 as a drug target and biomarker.

Protein Name: ACTR3B Pseudogene 2

The "ACTR3BP2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ACTR3BP2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets